CO has Significant Potential in a Variety of Ischemia-Reperfusion, Fibrotic, and Inflammatory Diseases
Delayed Graft Function (DGF)
There are >17K total kidney transplants per year in the US alone, with nearly half of the 13K cadaveric kidney transplants leading to delayed/slow graft function (DGF/SGF). DGF/SGF significantly increases the risk of acute and chronic organ failure. iCo for DGF would allow for decreased graft failure rates and improved graft function from donors after cardiac death (DCD) and extended criteria donors (ECD). This in turn would shorten transplant list wait times, reduce morbidity/mortality and follow-up dialysis, and reduce overall costs of successful transplants
Idiopathic Pulmonary Fibrosis (IPF)
IPF is a progressive fibrotic deterioration of lung function with a median survival time of under four years from diagnosis. Two recently approved medications only moderately slow progression, with significant adverse effects seen in trials, and like most other products in the pipeline involve a similar mechanism of action. iCO acts via multiple anti-fibrotic, anti-apoptotic, anti-inflammatory and vasodilatory pathways which should show synergy with Ofev®/Esbriet®, the two currently approved and widely prescribed IPF therapies.